Results 41 to 50 of about 7,470 (208)
Antimuscarinic drugs are generally thought to exert their therapeutic action on detrusor overactivity by reducing the ability of the detrusor muscle to contract.
Gillespie JI +3 more
core +4 more sources
ABSTRACT Introduction Antimuscarinics, as the current first‐line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta‐3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and ...
Felicity Smith +2 more
wiley +1 more source
Investigation of the mechanisms and modulation of irinotecan‐induced emesis in Suncus murinus
Abstract Background and Purpose Irinotecan is a widely used chemotherapeutic agent that frequently causes nausea and emesis. Its emetic mechanism of action is poorly understood and the choice of drugs to reduce nausea and emesis is largely empirical. Experimental Approach Using Suncus murinus, we examined (i) the dose–response and temporal profile of ...
Zengbing Lu +7 more
wiley +1 more source
Overactive bladder (OAB) syndrome is a chronic, debilitating disorder with physical, psychological, and social repercussions that considerably reduces the quality of life for 12-17% of the population.
Shoeb Alahmad +3 more
doaj +1 more source
Background To assess treatment persistence and adherence in men ≥45 years of age with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), using prescription records from the Netherlands IMS Lifelink™ LRx database ...
Marcus J. Drake +6 more
doaj +1 more source
Objective: To compare nerve growth factor (NGF) levels in patients who received antimuscarinic, versus onabotulinum toxin-A (onaBoNT-A) injection, as well as to investigate whether there is a correlation between NGF levels, and 8-item overactive bladder ...
Süleyman Sağır +5 more
doaj +1 more source
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza +12 more
wiley +1 more source
“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan +2 more
wiley +1 more source
Antimuscarinic drugs are generally thought to exert their therapeutic action on detrusor overactivity by reducing the ability of the detrusor muscle to contract.
Finney, Steven M. +4 more
core +1 more source
Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment [PDF]
Purpose: To identify incidence and risk factors of recurrence after discontinuation of successful antimuscarinic therapy in patients with overactive bladder (OAB). Materials and Methods: This was a prospective, multicenter trial.
Aram Kim +17 more
doaj +1 more source

